NCT02171741View on ClinicalTrials.gov

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2007

Conditions
Neoplasms
Interventions
DRUG

BIBW 2992

continuous daily dosing for 20 or 13 days

DRUG

Docetaxel

single infusion on day 1

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02171741 - Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter